Citation
Laurent, Cyril, et al. "Beneficial Effects of Caffeine in a Transgenic Model of Alzheimer's Disease-like Tau Pathology." Neurobiology of Aging, vol. 35, no. 9, 2014, pp. 2079-90.
Laurent C, Eddarkaoui S, Derisbourg M, et al. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging. 2014;35(9):2079-90.
Laurent, C., Eddarkaoui, S., Derisbourg, M., Leboucher, A., Demeyer, D., Carrier, S., Schneider, M., Hamdane, M., Müller, C. E., Buée, L., & Blum, D. (2014). Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiology of Aging, 35(9), 2079-90. https://doi.org/10.1016/j.neurobiolaging.2014.03.027
Laurent C, et al. Beneficial Effects of Caffeine in a Transgenic Model of Alzheimer's Disease-like Tau Pathology. Neurobiol Aging. 2014;35(9):2079-90. PubMed PMID: 24780254.
TY - JOUR
T1 - Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.
AU - Laurent,Cyril,
AU - Eddarkaoui,Sabiha,
AU - Derisbourg,Maxime,
AU - Leboucher,Antoine,
AU - Demeyer,Dominique,
AU - Carrier,Sébastien,
AU - Schneider,Marion,
AU - Hamdane,Malika,
AU - Müller,Christa E,
AU - Buée,Luc,
AU - Blum,David,
Y1 - 2014/03/29/
PY - 2013/08/21/received
PY - 2014/03/09/revised
PY - 2014/03/23/accepted
PY - 2014/5/1/entrez
PY - 2014/5/2/pubmed
PY - 2015/2/13/medline
KW - Alzheimer's disease
KW - Caffeine
KW - Caffeine metabolites
KW - THY-Tau22
KW - Tau
KW - Transgenic
SP - 2079
EP - 90
JF - Neurobiology of aging
JO - Neurobiol Aging
VL - 35
IS - 9
N2 - Tau pathology found in Alzheimer's disease (AD) is crucial in cognitive decline. Epidemiologic evidences support that habitual caffeine intake prevents memory decline during aging and reduces the risk to develop Alzheimer's disease. So far, experimental studies addressed the impact of caffeine in models mimicking the amyloid pathology of AD. However, in vivo effects of caffeine in a model of AD-like tauopathy remain unknown. Here, we evaluated effects of chronic caffeine intake (0.3 g/L through drinking water), given at an early pathologic stage, in the THY-Tau22 transgenic mouse model of progressive AD-like tau pathology. We found that chronic caffeine intake prevents from the development of spatial memory deficits in tau mice. Improved memory was associated with reduced hippocampal tau phosphorylation and proteolytic fragments. Moreover, caffeine treatment mitigated several proinflammatory and oxidative stress markers found upregulated in the hippocampus of THY-Tau22 animals. Together, our data support that moderate caffeine intake is beneficial in a model of AD-like tau pathology, paving the way for future clinical evaluation in AD patients.
SN - 1558-1497
UR - https://www.unboundmedicine.com/medline/citation/24780254/Beneficial_effects_of_caffeine_in_a_transgenic_model_of_Alzheimer's_disease_like_tau_pathology_
DB - PRIME
DP - Unbound Medicine
ER -
